Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Isao OhsawaDaisuke HondaYusuke SuzukiTomoo FukudaKeisuke KohgaEishin MoritaShinichi MoriwakiOsamu IshikawaYoshihiro SasakiMasaki TagoGreg ChittickMelanie CornpropstSharon C MurraySylvia M DoboEniko NagySharon Van DykeLacy ReeseJessica M BestHeather IoccaPhil CollisWilliam P SheridanMichihiro HidePublished in: Allergy (2020)
Orally administered, once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks and was safe and well tolerated, supporting its use as a prophylactic therapy in patients with type 1 or 2 HAE in Japan.